Frontlight ResearchEarly access
Not yet recruitingPhase 1/2
Scan tracer [68Ga]Ga-DOTA-SIGLEC-9 in rheumatoid arthritis, vasculitis and lung sarcoidosis
Tests an imaging tracer's safety and body spread in inflammatory disease patients and healthy volunteers.
Key facts
- Who runs it
- Turku University Hospital
- Where
- Finland1 site in 1 countryChoose a country to see its sites
- Registry title
- POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY STUDY FOR SAFETY, TOLERABILITY, BIODISTRIBUTION AND PERFORMANCE OF [68Ga]Ga-DOTA-SIGLEC-9 FOLLOWING A SINGLE INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, VASCULITIS OR PULMONARY SARCOIDOSIS AS WELL AS RADIATION DOSIMETRY, PLASMA PHARMACOKINETICS, BIODISTRIBUTION OF THE TRACER IN HEALTHY VOLUNTEERS
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 26 people, planned
- Started
- 1 Jan 2019
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Record updated
- 29 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active rheumatoid arthritis, vasculitis or pulmonary sarcoidosis, and also healthy volunteers. Each person gets one dose of a tracer called [68Ga]Ga-DOTA-SIGLEC-9 given into a vein, followed by a PET/CT scan.
- Age
- 18 Years and older
- Sex
- All sexes
- Disease stage
- Patients must have active rheumatoid arthritis, vasculitis or pulmonary sarcoidosis. Healthy volunteers can also join.
Where is this trial?
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Scan tracer [68Ga]Ga-DOTA-SIGLEC-9 in rheumatoid arthritis, vasculitis and lung sarcoidosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 29 January 2025